NEW YORK (
) hit a new 52-week low Thursday as it is currently trading at $20.37, below its previous 52-week low of $20.43 with 138,667 shares traded as of 1:15 p.m. ET. Average volume has been 541,900 shares over the past 30 days.
Acorda has a market cap of $868.5 million and is part of the
industry. Shares are down 24.6% year to date as of the close of trading on Wednesday.
Acorda Therapeutics, Inc., a commercial stage biopharmaceutical company, involves in the identification, development, and commercialization of therapies for multiple sclerosis (MS), spinal cord injury, and other nervous system disorders. The company has a P/E ratio of 54.8, below the average drugs industry P/E ratio of 59.2 and above the S&P 500 P/E ratio of 17.7.
- Practice your ACOR trading strategies and win cash in our stock game.
TheStreet Ratings rates Acorda as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year. You can view the full
or get investment ideas from our